TISIDB

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space. Note=99% of EC-SOD is anchored to heparan sulfate proteoglycans in the tissue interstitium, and 1% is located in the vasculature in equilibrium between the plasma and the endothelium.
Domain	PF00080 Copper/zinc superoxide dismutase (SODC)
Function	Protect the extracellular space from toxic effect of reactive oxygen intermediates by converting superoxide radicals into hydrogen peroxide and oxygen.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0000303 response to superoxide GO:0000305 response to oxygen radical GO:0001666 response to hypoxia GO:0006801 superoxide metabolic process GO:0006979 response to oxidative stress GO:0009636 response to toxic substance GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0019430 removal of superoxide radicals GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0036293 response to decreased oxygen levels GO:0046688 response to copper ion GO:0070482 response to oxygen levels GO:0071450 cellular response to oxygen radical GO:0071451 cellular response to superoxide GO:0072593 reactive oxygen species metabolic process GO:0098754 detoxification GO:0098869 cellular oxidant detoxification GO:1990267 response to transition metal nanoparticle GO:1990748 cellular detoxification
Molecular Function	GO:0004784 superoxide dismutase activity GO:0005507 copper ion binding GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0016209 antioxidant activity GO:0016721 oxidoreductase activity, acting on superoxide radicals as acceptor GO:1901681 sulfur compound binding
Cellular Component	GO:0005796 Golgi lumen GO:0005802 trans-Golgi network GO:0031984 organelle subcompartment GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-2262752: Cellular responses to stress R-HSA-3299685: Detoxification of Reactive Oxygen Species

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SOD3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SOD3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SOD3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.635	0.0554
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-2.796	0.29
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.762	0.656
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.21	0.783
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.074	0.971
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.562	0.814
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.444	0.386
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.518	0.623
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.383	0.741
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.704	0.261
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.603	0.47
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.712	0.000598

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SOD3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOD3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOD3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOD3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOD3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SOD3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SOD3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SOD3
Name	superoxide dismutase 3, extracellular
Aliases	EC-SOD; Extracellular superoxide dismutase [Cu-Zn]
Chromosomal Location	4p15.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SOD3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SOD3